Sign in
Stories
Biopharma Companies Announce Public Offerings
Share
AI-Driven Discovery and Insurance Innova...
Adial Pharmaceuticals Boosts Funds for A...
Advancements in Gene Editing and Cancer ...
10X Capital Venture Acquisition Corp. II...
4P-Pharma Secures €15 Million Funding
AB Science's Medical Breakthrough Webcas...
Overview
API
Biopharmaceutical companies ArriVent and Sagimet Biosciences announce public offerings, with ArriVent pricing its initial public offering at $18.00 per share, expected to raise $175.0 million, while Sagimet prices its offering at $12.50 per share, expected to raise $112.5 million. Both companies are focused on developing differentiated medicines for cancer treatment, with ArriVent initially focusing on solid tumors and Sagimet developing FASN inhibitors for NASH treatment.
Ask a question
How do these offerings reflect the current investment climate and market demand for biopharmaceutical innovations?
How might the public offerings impact the financial position and future development of ArriVent and Sagimet Biosciences?
What are the potential implications of these public offerings for the biopharmaceutical industry and the treatment of cancer and NASH?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Jan 2024
Coverage